← Patent-cliff monitor small molecule KLISYRI TIRBANIBULIN
Loss of exclusivity September 2038 latest FDA-listed patent expiry
Company Almirall → See this company's full patent-cliff portfolio Drug detail Brand name KLISYRI Active ingredient TIRBANIBULIN Strength 1% Dosage form OINTMENT Route TOPICAL Modality Small molecule FDA approval December 2020 Marketing status RX
Listed patents Patent Expires Type 10669236 September 2038 substance, product 10617693 March 2038 use U-3015 11497750 March 2038 use U-3015 12667576 March 2038 use U-4577 7300931 December 2030 substance, product 7851470 February 2029 substance, product 10323001 December 2027 product
Regulatory exclusivity Code Expires D-192 June 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.